Overview

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Status:
Completed
Trial end date:
2018-05-09
Target enrollment:
Participant gender:
Summary
This research study is studying a chemotherapy as a possible treatment for recurrent glioblastoma that has not responded to bevacizumab. The name of the study drug involved in this study is Ponatinib.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Bevacizumab
Ponatinib